These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20027114)

  • 1. Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Genet Med; 2010 Jan; 12(1):25-31. PubMed ID: 20027114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
    Hessock M; Brewer T; Hutson S; Anderson J
    Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral.
    Bellcross CA; Leadbetter S; Alford SH; Peipins LA
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):728-35. PubMed ID: 23371291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer.
    Cragun D; Bonner D; Kim J; Akbari MR; Narod SA; Gomez-Fuego A; Garcia JD; Vadaparampil ST; Pal T
    Breast Cancer Res Treat; 2015 May; 151(1):169-76. PubMed ID: 25868867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceptions of high-risk care and barriers to care among women at risk for hereditary breast and ovarian cancer following genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    J Genet Couns; 2010 Feb; 19(1):44-54. PubMed ID: 19809867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Implementing B-RST
    Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
    Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together.
    Demarco TA; Nusbaum RH; Peshkin BN; Patenaude AF; Schneider KA; Garber JE; Valdimarsdottir HB; Tercyak KP
    Patient Educ Couns; 2010 Jan; 78(1):29-33. PubMed ID: 19545972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
    de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
    Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.
    Hurley K; Rubin LR; Werner-Lin A; Sagi M; Kemel Y; Stern R; Phillips A; Cholst I; Kauff N; Offit K
    Cancer; 2012 Dec; 118(24):6270-7. PubMed ID: 22736296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    Kukafka R; Pan S; Silverman T; Zhang T; Chung WK; Terry MB; Fleck E; Younge RG; Trivedi MS; McGuinness JE; He T; Dimond J; Crew KD
    JAMA Netw Open; 2022 Jul; 5(7):e2222092. PubMed ID: 35849397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.